Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: AI
Indian food regulatory body FSSAI has barred the sale of select products produced by one of the biggest FMCG companies in India.
The Food Safety and Standards Authority of India prohibited Dabur India from selling its popular household products like honey, cow ghee, and edible oils with '100 percent' claims.
On Monday, FSSAI shared a social media post, announcing that it has banned the sale of a few products produced by Dabur India over misleading claims.
In a Tweet, it said that the FMCG giant has been asked to stop selling products like honey, apple cider vinegar, virgin coconut oil, sesame oil, cow ghee, coconut water, coconut milk, and other products due to various non-compliances.
The following violations were listed by the food regulatory body:
FSSAI said that some Dabur products were being sold on the company's website with misleading '100% percent' claims like '100% Natural', '100% Pure', '100% Purity Guaranteed', '100% Organic, and '100% Tender Coconut Water'.
FSSAI said that Dabur Homemade Coconut Milk was being sold with the claim '100% Purity', which is in violation with its rules.
According to FSS (Advertising & Claims) Regulations, 2018, the use of claims with '100%' is prohibited as it's an ambiguous term which cannot be verified. It further said that such claims can mislead the consumers.
Also read: FSSAI Bans Some Liquor Produced by India's Largest Alcohol Company Over Artificial Flavouring
Furthermore, its products like Dabur Himalayan Organic Apple Cider Vinegar and Dabur Organic Honey were found showcasing Jaivik Bharat Logo without an organic endorsement by FSSAI.
The Jaivik Bharat logo is specifically issued to authentic organic food products in order to distinguish them from non-organic items. It is meant to show compliance with Indian organic standards.
The regulatory body said that by doing so, the company violated FSS (Organic Foods) Regulations, 2017.
Also read: No Junk Food Near Schools! Maharashtra FDA Bans Sale Of Foods & Drinks High In Fat, Salt & Sugar
This is not the first time FSSAI has brought these violations to the company's attention. In its notice, it said that Dabur paid no heed to an earlier notice which directed them to discontinue products with '100% claims'.
It said that the company failed to take "satisfactory corrective action".
Besides prohibiting the sale of these products, FSSAI has asked Dabur to submit an Action Taken Report (ATR) within 15 days.
Also read: 60% Urban Indians Not Confident About Ghee Purity Despite FSSAI Crackdown
FSSAI's action is part of its broader strategy to stop the sale of products with misleading claims and brand names.
Recently, show-cause notices were sent to brands like Lotte India, Kubera Foods, and Ferns N Petals Pvt Ltd over allegedly misleading claims such as "100% Natural," "100% Vegetarian," and chocolate labelling issues.
It also flagged Heritage Fresh Paneer for using the term "Fresh Paneer" to market its products.
In June, brands like Nestlé, KFC, Open Secret, Emami Healthy & Tasty, Storia Juice, Two Brothers Organic Farms, Healthy Master, Neuherbs, The Health Factory, Troovy, Healthy Choice, Organic Wisdom, Shine Organic, World of Organic, and Lota Water were sent notices for misleading brand names and health claims like "organic," "healthy," "zero maida," and similar marketing claims that may violate labelling regulations.
Credit: iStock
The currently used breast cancer screening referral criteria at the NHS are missing up to 95% of women under 50 who are at higher risk of developing breast cancer in the next decade, according to a new study.
Published in the British Journal of Cancer, the study found that a more comprehensive, personalized risk assessment could identify 8 times as many women at risk as the current NICE guidelines.
Also read: New York Reports 3 Suspected Rabbit Fever Cases: What Is Tularemia?
In England, women at higher risk of breast cancer are typically identified after being referred by their GP based on family history, following criteria set by the National Institute for Health and Care Excellence (NICE), under the NHS.
The researchers from the University of Cambridge and The Institute of Cancer Research, London, analyzed data from 1,258 women under the age of 50.
They found that the criteria would refer only 1.4% of women for specialist assessment and identify just 4.4% of women who went on to develop breast cancer within the next 10 years.
The researchers then evaluated BOADICEA, a multifactorial risk model that combines:
Using this model, 26.5% of women were classified as having above-average risk and referred for further assessment. This approach identified 34.8% of women who developed breast cancer within the following 10 years—around eight times more than the current NICE criteria.
One major reason for the gap is that 73% of women under 50 who developed breast cancer had no family history of the disease, making them unlikely to qualify for referral under existing guidelines.
"We need to get better at identifying women at highest risk of breast cancer so that we can intervene early, when there are more options for treating, or even preventing, their disease," said Dr Juliet Usher-Smith from the Department of Public Health and Primary Care at the University of Cambridge.
Read More: UK Woman Becomes World-First To Receive Experimental Cell Therapy For Ovarian Cancer
A second study by the same research team found strong public support for proactive breast cancer risk assessments for women aged 30 to 49, instead of relying on women to seek GP referrals because of family history.
They found that women preferred:
Dr Sowmiya Moorthie, Senior Strategic Evidence Manager at Cancer Research UK, said broader risk assessment could help more women receive personalized care. However, she noted that further research is needed to understand the impact on NHS staffing, equipment, and patient experience, while ensuring any new approach remains accessible and equitable.
She also emphasized that maintaining a healthy weight, limiting alcohol intake, and seeking medical advice for any unusual breast changes remain important ways to reduce risk and improve outcomes through early diagnosis.
Breast cancer is the most common cancer worldwide, with steady increases in incidence over the last few decades. It accounts for around one in four cases of cancer and 15 per cent of cancer deaths in women, and is one of the leading causes of death in women under 50.
Breast cancer is the most common cancer in the UK, with around 59,400 new cases diagnosed annually and roughly 11,200 deaths each year. About one in seven women in the UK develops the disease in their lifetime, though survival rates are high, with nearly 90% surviving for five years or more.
Credit: iStock
Health officials in New York have reported at least three suspected cases of tularemia, a rare bacterial illness also known as rabbit fever.
The disease can spread through the bite of infected ticks or deer flies, or through contact with infected animals, particularly rabbits and rodents.
The Suffolk County Department of Health said laboratory testing is required to confirm the suspected cases, a process that may take several weeks.
"Confirmation of a tularemia diagnosis requires a combination of laboratory testing and fulfillment of specific clinical or epidemiologic criteria," the department told ABC 7, New York.
"The laboratory testing to confirm a tularemia diagnosis may take several weeks."
Tularemia is most commonly reported between May and September, according to the US Centers for Disease Control and Prevention (CDC).
Fewer than 200 cases are reported annually in the US, based on CDC data from 2019 to 2023. Although still rare, reported cases have been increasing.
In Suffolk County, Long Island:
Tularemia is a rare but potentially serious bacterial infection caused by Francisella tularensis, according to the CDC.
The disease can affect the skin, lymph nodes, eyes, throat, lungs, and other organs depending on how the bacteria enter the body.
People can become infected through:
According to the CDC, the case fatality rate is typically below 2%, though it can be higher depending on the bacterial strain and type of illness.
There are six main forms of tularemia:
Symptoms vary depending on the type of infection but commonly include:
Because tularemia is rare, it can be difficult to diagnose, and its symptoms often resemble more common illnesses.
Tularemia is highly treatable with antibiotics when diagnosed promptly.
The CDC noted that a vaccine previously used to protect laboratory workers is currently under review by the US Food and Drug Administration and is not generally available.
The CDC recommends the following precautions:
© 2024 Bennett, Coleman & Company Limited